AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...

AstraZeneca has signed a research agreement worth more than $5 billion with Chinese drugmaker CSPC Pharmaceutical Group, the ...

AstraZeneca has penned a drug discovery pact focused on chronic diseases with China's CSPC Pharma. The FDA has halted new trials that export U.S. individuals' living cells to China. | AstraZeneca has ...

Under terms of the deal, CSPC will receive $110 million upfront, with potential milestone payments reaching up to $5.22 ...

The deal with China’s CSPC Pharmaceuticals, focused on AI-driven research, aims to advance the discovery and development of ...

CSPC will use its artificial-intelligence-driven, dual-engine efficient drug discovery platform to analyze the binding ...

The announcement builds on AZ's announcement earlier this year that it will invest $2.5 billion in an R&D facility in China, ...

The drug licensing talks cover the development, production and sale of a targeted cancer therapy and other CSPC Pharma ...

AstraZeneca is paying CSPC Pharmaceutical Group $110 million up front to tap that China-based biotech’s artificial intelligence-driven technology for discovering and developing novel oral drugs.

Davey D and Lina Girl discuss the hottest trends in technology from gaming to life-saving devices to apps that make you ...

AstraZeneca said it entered into a strategic research collaboration with China’s CSPC Pharmaceuticals, focused on artificial intelligence-driven research, valued at up to $5.33 billion.